1. Indications and Usage
\nSpinal Muscular Atrophy (SMA):
\nIndicated for the treatment of patients with spinal muscular atrophy (SMA).
\nApplicability: Approved for infants, children, and adults across all SMA types.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intrathecal Injection ONLY. Must be administered by a healthcare professional experienced in intrathecal injections.
\nRecommended Dosage:
\nDose: 12 mg (5 mL) per dose.
\nLoading Dose: Administer at Day 0, Day 14, Day 28, and Day 63 (4th bolus).
\nMaintenance Dose: Administer once every 4 months after the loading dose.
\nAdministration Instructions:
\nPre-procedure: Drain cerebrospinal fluid (CSF) volume equivalent to the injected drug volume before administration.
\nPreparation: Allow the vial to reach room temperature naturally. Do not dilute or shake.
\n3. Mechanism of Action
\nAntisense Oligonucleotide (ASO):
\nNusinersen is an ASO that selectively binds to a specific sequence in the SMN2 pre-mRNA transcript.
\nSplicing Modification:
\nIt modulates splicing to increase the inclusion of Exon 7, thereby producing full-length, functional Survival of Motor Neuron (SMN) protein.
\n4. Safety and Warnings
\nRenal Toxicity:
\nMonitor for renal toxicity. Perform urinalysis (preferably first morning urine) and monitor protein levels before each dose.
\nCoagulation and Thrombocytopenia:
\nMonitor platelet counts and coagulation parameters (e.g., PT, aPTT) before each dose.
\nPost-Lumbar Puncture Complications:
\nMonitor for headache, back pain, vomiting, hypertension, tachycardia, and urinary retention.
\nRespiratory Infections:
\nMonitor for respiratory infections, as patients with SMA are at increased risk.
\n5. Adverse Reactions
\nMost Common:
\nPost-procedure complications (headache, back pain, vomiting), respiratory infections (pneumonia, influenza), constipation, and urinary retention.
\n6. Drug Interactions
\nMetabolism:
\nNusinersen is not metabolized by CYP450 enzymes.
\nAnticoagulants:
\nConcomitant use with anticoagulants or antiplatelet agents may increase the risk of bleeding during lumbar puncture.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Nusinersen Sodium.
\nAvailable Strength: 12 mg\/5 mL (2.4 mg\/mL) in single-use vials.
\nStorage:
\nStore in a refrigerator at 2-8\u00b0C. Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u8bfa\u897f\u90a3\u751f\u94a0\u00ae(Spinraza\u00ae)
\nGeneric Name: Nusinersen Sodium
\nStrength: 12mg per 5mL per vial, single-use vial
\nManufacturer: Ionis Pharmaceuticals \/ Catalent Indiana, LLC
\nMarketing Authorization Holder: Biogen International GmbH
\nApproval Date in China: February 25, 2019
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20190009
\nStorage: Store refrigerated at 2\u2103\uff5e8\u2103, protected from light, do not freeze; keep away from children.<\/p>\n
Price&Cost:Contact Us now for the best price of Nusinersen Sodium\uff08Spinraza\uff09<\/p>\n","protected":false},"featured_media":3473,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25],"product_tag":[],"class_list":["post-3472","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n